Using high molecular weight hyaluronic acid to treat lung injury from severe pneumonia or sepsis
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis
This study is looking at whether a special type of hyaluronic acid can help improve lung function and reduce inflammation in patients with serious lung problems caused by severe pneumonia or sepsis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10991624 on NIH RePORTER |
What this research studies
This research investigates the potential of high molecular weight hyaluronic acid (HMW HA) as a treatment for acute lung injury caused by severe bacterial pneumonia or sepsis. The study aims to understand how HMW HA can help restore the normal function of the lung's air-blood barrier, which is often compromised in patients with acute respiratory distress syndrome (ARDS). By administering HMW HA, the researchers hope to reduce inflammation and improve lung function in critically ill patients. The approach is based on previous findings that suggest HMW HA has beneficial properties that counteract the harmful effects of its low molecular weight counterpart.
Who could benefit from this research
Good fit: Ideal candidates for this research are critically ill patients diagnosed with acute lung injury resulting from severe bacterial pneumonia or sepsis.
Not a fit: Patients with lung injuries not related to bacterial pneumonia or sepsis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that significantly reduces mortality and improves recovery in patients suffering from ARDS due to pneumonia or sepsis.
How similar studies have performed: Previous studies have shown promising results with the use of high molecular weight hyaluronic acid in treating lung disorders, indicating potential for success in this novel application.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Lee, Jae Woo — University of California Los Angeles
- Study coordinator: Lee, Jae Woo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.